Aerosolized Syk antisense suppresses Syk expression, mediator release from macrophages, and pulmonary inflammation

G R Stenton1, M K Kim, O Nohara

  • 1Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Insights

Aerosolized Syk antisense oligodeoxynucleotides (ASO) reduced Syk protein tyrosine kinase (PTK) expression in rat lungs. Syk ASO treatment suppressed inflammatory mediator release and pulmonary inflammation, indicating potential asthma therapy.

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Syk protein tyrosine kinase (PTK) is crucial for signaling in leukocytes, particularly in macrophages.
  • Fcgamma-receptor activation in macrophages triggers Syk PTK phosphorylation and downstream events like phagocytosis and mediator release.

Purpose of the Study:

  • To investigate the efficacy of aerosolized Syk antisense oligodeoxynucleotides (ASO) in reducing Syk PTK expression and Syk-dependent pulmonary inflammation in vivo.
  • To assess the impact of Syk ASO on mediator release from alveolar macrophages.

Main Methods:

  • Administration of Syk ASO via aerosol to rat lungs.
  • Quantitative reverse transcription PCR (RT-PCR) and RT-in situ PCR to measure Syk mRNA expression.
  • Western blot analysis to confirm Syk PTK protein expression levels.
  • Stimulation of alveolar macrophages with IgG-anti-IgG complexes to assess mediator release (nitric oxide, TNF, IL-1beta).
  • Evaluation of antigen-induced pulmonary inflammation.

Main Results:

  • Aerosolized Syk ASO significantly reduced Syk mRNA and protein tyrosine kinase expression in rat alveolar macrophages.
  • Syk ASO treatment suppressed Fcgamma-receptor-mediated nitric oxide and TNF production by alveolar macrophages.
  • Fcgamma-receptor-induced IL-1beta release remained unaffected by Syk ASO treatment.
  • Syk ASO administration effectively suppressed antigen-induced pulmonary inflammation.

Conclusions:

  • Aerosolized Syk ASO is effective in reducing Syk PTK expression and associated inflammatory responses in the lungs.
  • Syk ASO demonstrates potential as an anti-inflammatory therapeutic agent for respiratory disorders like asthma.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...